BridgeBio Pharma (BBIO) Receivables - Net (2021 - 2026)
BridgeBio Pharma (BBIO) posted Receivables - Net of $205.2 million for Q1 2026, up 47.17% sequentially from $139.4 million in Q4 2025, and up 78.05% YoY from $115.3 million in Q1 2025.
BridgeBio Pharma (BBIO) Receivables - Net (2021 - 2026) Analysis & Trends
BridgeBio Pharma has reported Receivables - Net for 6 years, with the latest figure at $205.2 million in Q1 2026.
- Quarterly Receivables - Net rose 78.05% year-over-year to $205.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205.2 million (up 78.05% YoY) and the FY2025 annual result came in at $139.4 million, up 2853.07% from the prior year.
- Receivables - Net grew to $205.2 million in Q1 2026 per BBIO's latest filing, from $139.4 million in the prior quarter.
- Over five years, Receivables - Net peaked at $235.5 million in Q1 2024 and troughed at $478000.0 in Q3 2024.
- A 5-year average of $58.6 million and a median of $17.1 million in 2022 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2024 and 2025: Receivables - Net plunged 92.34% in 2024, then surged 24276.15% in 2025.
- Over 5 years, Receivables - Net stood at $17.1 million in 2022, then tumbled by 89.75% to $1.8 million in 2023, then soared by 169.67% to $4.7 million in 2024, then jumped by 2853.07% to $139.4 million in 2025, then jumped by 47.17% to $205.2 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $205.2 million, $139.4 million, and $116.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 254.48 Mn |
| Jun 30, 2026 | 254.48 Mn |
| Mar 31, 2026 | 205.23 Mn |
| Mar 31, 2026 | 205.23 Mn |
| Dec 31, 2025 | 139.44 Mn |
| Dec 31, 2025 | 139.44 Mn |
| Sep 30, 2025 | 116.52 Mn |
| Sep 30, 2025 | 116.52 Mn |
| Jun 30, 2025 | 76.87 Mn |
| Jun 30, 2025 | 76.87 Mn |
| Mar 31, 2025 | 115.27 Mn |
| Mar 31, 2025 | 115.27 Mn |
| Dec 31, 2024 | 4.72 Mn |
| Dec 31, 2024 | 4.72 Mn |
| Sep 30, 2024 | 478,000.00 |
| Sep 30, 2024 | 478,000.00 |
| Jun 30, 2024 | 660,000.00 |
| Jun 30, 2024 | 660,000.00 |
| Mar 31, 2024 | 235.49 Mn |
| Mar 31, 2024 | 235.49 Mn |